THERAMAP Trademark

Trademark Overview


On Thursday, May 18, 2017, a trademark application was filed for THERAMAP with the United States Patent and Trademark Office. The USPTO has given the THERAMAP trademark a serial number of 87455849. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, December 13, 2024. This trademark is owned by Navican Genomics, Inc.. The THERAMAP trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Dispensing of pharmaceuticals; medical and pharmaceutical consultation; pharmaceutical advice; pharmaceutical compounding services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, providing personalized drug therapy management programs to cancer patients based on the patient's genetic testing results; genetic testing for medical purposes; genetic testing for cancer diagnosis, treatment and prevention purposes; providing genetic sequencing and consulting services via website designed to provide cancer patients and oncologists with custom tailored information about the range of possible treatments and drug therapies for a particular cancer; providing information to patients and physicians via a website to recommend cancer treatment and drug therapies based on the patient's genetic testing results; providing personalized drug therapy services for cancer patients; drug utilization review dispensing services...
theramap

General Information


Serial Number87455849
Word MarkTHERAMAP
Filing DateThursday, May 18, 2017
Status710 - CANCELLED - SECTION 8
Status DateFriday, December 13, 2024
Registration Number5482458
Registration DateTuesday, May 29, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 3, 2017

Trademark Statements


Goods and ServicesDispensing of pharmaceuticals; medical and pharmaceutical consultation; pharmaceutical advice; pharmaceutical compounding services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, providing personalized drug therapy management programs to cancer patients based on the patient's genetic testing results; genetic testing for medical purposes; genetic testing for cancer diagnosis, treatment and prevention purposes; providing genetic sequencing and consulting services via website designed to provide cancer patients and oncologists with custom tailored information about the range of possible treatments and drug therapies for a particular cancer; providing information to patients and physicians via a website to recommend cancer treatment and drug therapies based on the patient's genetic testing results; providing personalized drug therapy services for cancer patients; drug utilization review dispensing services via a website, namely, identifying cancer drug therapies based on a patient's genetic testing results prior to dispensing medications; developing and managing comprehensive treatment programs involving drug therapy; physician support services in the nature of providing consultation in the dispensing of prescription drugs for persons with particular cancers; providing medical evaluations of patients to determine acceptability for participation in clinical trials; providing healthcare counseling, screening, diagnosis, prognosis, treatment, relapse, palliative, integrative medicine, survivorship, and other related medical information in the field of oncology; providing a database in the field of oncology and featuring inputting and collection of data and information all for treatment and diagnosis purposes; healthcare consultation in the field of cancer treatment research, namely, advising patients on cancer treatment research studies in which they might participate for purposes of treating their conditions; providing an online searchable database in the fields of oncology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis for personalized diagnosis, treatment and prevention of cancer

Classification Information


International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, December 13, 2024
Primary Code044
First Use Anywhere DateThursday, June 1, 2017
First Use In Commerce DateThursday, June 1, 2017

Trademark Owner History


Party NameIHC HEALTH SERVICES, INC.
Party Type31 - New Owner After Registration
Legal Entity Type54 - NOT AVAILABLE
AddressSALT LAKE CITY, UT 84111

Party NameNavican Genomics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Party NameNavican Genomics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Party NameNavican Genomics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events


Event DateEvent Description
Monday, May 22, 2017NEW APPLICATION ENTERED
Wednesday, May 24, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 17, 2017ASSIGNED TO EXAMINER
Tuesday, October 3, 2017PUBLISHED FOR OPPOSITION
Tuesday, October 3, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, April 6, 2018USE AMENDMENT FILED
Tuesday, April 24, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, April 25, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, April 26, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, May 29, 2018REGISTERED-PRINCIPAL REGISTER
Wednesday, August 14, 2019AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Thursday, August 24, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 13, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 28, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, April 6, 2018TEAS STATEMENT OF USE RECEIVED
Tuesday, April 24, 2018STATEMENT OF USE PROCESSING COMPLETE
Monday, May 29, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, December 13, 2024CANCELLED SEC. 8 (6-YR)